Reduced Energy Per Cycle, a Marker of Glutamatergic Synaptic Strength, in Individuals Diagnosed with PTSD and Depression

Lynnette A. Averill, PhD [1,2,3,4], Lihong Jiang, PhD [5], Prerana Purohit, MA [1,4], Anastasia Coppoli, MS [5], Christopher L. Averill, BS [1,2,3,4], Jeremy Roscoe, BS[1,4], Benjamin Kelmendi, MD [1,4], Henk M. De Feyter, PhD [5], Robin A de Graaf, PhD [5], Ralitza Gueorguieva, PhD [6], Gerard Sanacora, MD, PhD [1,4], John H. Krystal, MD [1,4], Douglas L. Rothman, PhD [5], Graeme F. Mason, PhD [4,5], Chadi G. Abdallah, MD [1,2,3,4,7,*]

[1] National Center for PTSD – Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA

[2] Michael E. DeBakey VA Medical Center, Houston, TX, USA

[3] Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, USA

[4] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

[5] Yale Magnetic Resonance Research Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, CT, USA

[6] Department of Biostatistics, School of Public Health, Yale University School of Medicine, New Haven, CT, USA

[7] Core for Advanced Magnetic Resonance Imaging (CAMRI), Baylor College of Medicine, Houston, TX, USA

Running Title: Synaptic Strength in Trauma Psychopathology

Corresponding author: Chadi G. Abdallah, M.D.; Menninger Department of Psychiatry, Baylor College of Medicine; 1977 Butler Blvd, E4187, Houston, TX, 77030; *Tel:* +1 (347) 987-0717; *Email:* chadi.abdallah@bcm.edu

ABSTRACT

Trauma and chronic stress are believed to induce and exacerbate psychopathology by disrupting glutamate synaptic connectivity. In this pilot study, we utilized energy-per-cycle (EPC), a novel putative biomarker of glutamatergic synaptic strength, to investigate the role of prefrontal neurotransmission in trauma psychopathology. Healthy control (n=18) and patients with comorbid posttraumatic stress and major depressive disorders (PTSD+MDD; n=16) completed ^{13}C-acetate magnetic resonance spectroscopy scans to estimate prefrontal EPC, which is the ratio of neuronal energetic needs per glutamate neurotransmission cycle (V_{TCA}/V_{Cycle}). Patients with PTSD+MDD were found to have 28% reduction in prefrontal EPC (t=3.0; df=32, p=0.005). There was no effect of sex on EPC, but age was negatively associated with prefrontal EPC across groups (r=–0.46, n=34, p=0.006). Controlling for age did not affect the study results. Exploratory analyses found antidepressants to have statistically significant effects ($F_{(2,30)}$=5.3, p=0.01), with the lowest EPC in the unmedicated PTSD+MDD participants (p=0.003). Patients with comorbid PTSD and MDD have reduced prefrontal glutamatergic synaptic strength, as estimated by EPC. Antidepressant treatment appears to partially normalize the prefrontal EPC deficits. These findings suggest that reduced glutamatergic synaptic strength may contribute to the pathophysiology of comorbid PTSD and MDD and might be targeted by novel treatments.

INTRODUCTION

Stressors, whether acutely overwhelming or chronic, may trigger or exacerbate posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) [1]. While the neurobiology of trauma and stress is not fully known [2], converging evidence suggest a critical role for glutamatergic synaptic connectivity alterations that produce the dysfunction of brain networks regulating memory and emotion associated with the emergence of symptoms [3-5]. This hypothesis is emerging from many sources of data, including preclinical and postmortem data, and indirect human *in vivo* findings from gross brain structure, functional connectivity, total neurochemical levels, or various receptors binding potentials [4, 6, 7]. Yet, a major obstacle in the field remains the lack of a more direct and dynamic assessment of glutamatergic synaptic strength *in vivo* in patients.

Here, we report an exploration of a novel metric of glutamate function that is believed to directly reflect glutamatergic synaptic strength [8]. Synaptic strength is defined as the magnitude of the postsynaptic response to a presynaptic action potential. Traditionally, changes in synaptic strength, such as long-term potentiation or long-term depression, are measured using electrophysiologic techniques [9]. However, considering the tight coupling between synaptic signaling and brain energetics [10], it is possible to infer overall glutamatergic synaptic strength within a brain region based on concurrent measurement of the rate of neuronal oxidative energy production (V_{TCAn}) and glutamate neurotransmission cycling (V_{Cycle}) [8]. Briefly, brain energy budget calculations indicate that cerebral signaling costs approximately 80% of total neuronal energy and that the majority of signaling energy is used on glutamate postsynaptic transmission and action potentials (~71%) with only 9% spent on glutamate release and cycling [11, 12]. In fact, a majority of the currently available functional neuroimaging tools [e.g., functional magnetic resonance imaging (fMRI) and fluorodeoxyglucose positron emission tomography (FDG-PET)] are based on the experimental observation that brain energy metabolism is directly related to neuronal signaling [13]. One limitation of fMRI and FDG-PET is that they lack the capacity to concurrently measure the rate of synaptic glutamate release (V_{Cycle}). The aim of this pilot PTSD+MDD study is to investigate energy per cycle (EPC; i.e., V_{TCAn}/V_{Cycle} ratio) as a putative biomarker directly related to glutamatergic synaptic strength [8].

Preclinical studies suggest that traumatic and chronic stress reduce glutamate synaptic density, downregulate postsynaptic ionotropic glutamate receptors, and alter cortical functional connectivity reflecting overall reduction in prefrontal synaptic strength [14]. In humans, various brain imaging findings have been considered as biomarkers of this stress-related synaptic dysconnectivity [1, 15-17]. In particular, PTSD and MDD were repeatedly associated with gray matter deficits, especially in the prefrontal cortex. Reductions in cortical volume and thickness were reported in individual and meta-analysis studies [18-21]. Similarly, volumetric and shape analyses correlated trauma and stress psychopathology with gray matter deficit [22-24]. At the functional level, task and connectivity studies have identified broad circuit and large-scale brain network disturbances in trauma and stress-related disorders [4, 25, 26]. Moreover, disruption in global brain connectivity in the prefrontal gray matter was repeatedly related to the pathology and treatment of PTSD and MDD [27-38]. At the neurochemical level, studies have investigated total levels of glutamate or binding potential of glutamate receptors and glutamate-related vesicles [6, 34, 39-44]. These approaches have numerous strengths including wide availability,

good space and time resolutions, and ability to conduct whole brain assessments or study the full connectome. A main impediment to the utility of these previously identified biomarkers is the high overlap between healthy control participants and patients [45]. Another limitation is the complexity in interpreting the findings, as these measures do not specifically assess synaptic glutamate transmission but rather upstream input (e.g., glutamate receptors or vesicles) or downstream output (e.g., functional connectivity). The neuropsychiatry field may greatly benefit from establishing a biomarker that is directly related to glutamate synaptic neurotransmission, especially if this biomarker is tightly controlled in normal conditions.

[13]C Magnetic Resonance spectroscopy (^{13}C MRS), combined with the stable isotope ^{13}C acetate, is a specialized method that measures glutamatergic synaptic strength. ^{13}C MRS provides a measure of EPC that is the ratio of the rate of neuronal energy production divided by the rate of glutamate/glutamine cycling (V_{TCAn}/V_{cycle}). This ratio is equivalent to the neuronal energy consumed per glutamate cycle. EPC is a biomarker highly preserved across species and is a unique measure of glutamatergic synaptic strength [46-48]. Strength is defined as the synaptic energy consumption (in units of glucose molecules oxidized) required to support the depolarization induced by the release of one neurotransmitter glutamate molecule. These are the major energy consuming processes that contribute to the EPC ratio. Here, we used advanced methods for acquiring ^{13}C MRS in the human frontal lobe [49-52], a brain region closely related to psychopathology that was not previously accessible to ^{13}C MRS studies [48].

In this initial pilot study, we aimed to demonstrate altered glutamatergic synaptic strength, as measured by EPC, in the prefrontal cortex of patients with comorbid PTSD and MDD, compared to healthy control. We hypothesized that the PTSD+MDD participants will present significant reduction in prefrontal EPC. Considering that serotonergic reuptake inhibitors (SRIs) are thought to at least partially reverse stress-related synaptic dysconnectivity, we also conducted a secondary exploratory analysis to determine whether SRIs normalize prefrontal EPC in medicated PTSD+MDD patients.

METHODS

Study Participants

Healthy control and individuals diagnosed with comorbid PTSD and MDD between the ages of 18 and 65 were included in this study. All study procedures were approved by the Yale institution review board. All participants completed an informed consent process prior to enrollment.

Participants had no contraindication to magnetic resonance imaging, no dementia or mental retardation, no traumatic brain injury, no unstable medical condition, no pregnancy or breastfeeding, and were on a medically accepted birth control method. A negative urine toxicology test and, for women, a negative pregnancy test were required. Healthy participants were excluded if they had a lifetime history of any psychiatric disorder. PTSD+MDD participants were required to have: 1) current comorbid PTSD and MDD diagnoses as determined by a structured interview; 2) have been on stable antidepressant or on no antidepressants for at least 4 weeks; 3) no diagnosis of bipolar or psychotic disorder; 4) no

current substance/alcohol use disorder; 5) no current serious suicide risk; and 6) no current treatment with select medications that modulate excitatory aminoacid transporters, e.g., riluzole, ceftriaxone, pentoxifylline. The PTSD checklist (PCL) and Quick Inventory of Depressive Symptomatology (QIDS) self-report of 16 items were completed to assess PTSD and depression severity, respectively [53, 54].

^{13}C MRS Acquisition & Processing

Prefrontal ^{13}C MRS acquisition and preprocessing followed our previously established procedures [8]. MRS data were acquired on a 4.0 T whole-body magnet interfaced to a Bruker AVANCE spectrometer (Bruker Instruments, Billerica, MA, USA). Subjects were placed supine in the magnet, with their head immobilized with foam. An RF probe consisting of one circular ^{13}C coil (8.5 cm $\varnothing$) and two circular, quadrature driven ^{1}H RF coils (12.5 cm $\varnothing$) were used for acquisition of ^{13}C MR spectra from the frontal lobe (Fig. S1 A-B). Following tuning and acquisition of scout images, second-order shimming of the region of interest (ROI) was performed using phase mapping provided by Bruker.

^{13}C MR spectra were acquired with a pulse-acquire sequence using an adiabatic 90˚ excitation pulse and optimized repetition time (offset 180 ppm, TR 6s). Nuclear Overhauser enhancement (nOe) was achieved by applying ^{1}H block pulses before the ^{13}C excitation pulse. ^{1}H decoupling during acquisition consists of pseudo noise decoupling as described by Li *et al.* [50], to decouple the long-range ^{1}H-^{13}C coupling of the carboxylic carbon positions. The pseudo noise decoupling pulse has a constant amplitude and the phase of each 1.2-ms unit pulse is randomly assigned to either 0° or 180°. Following the start of [1 ^{13}C]-acetate infusion, 6.5-minute blocks of MR spectra were acquired for 120 minutes (Fig. S1 C & S2).

^{13}C MRS processing was conducted while blinded to the clinical data. Briefly, steady-state spectra were averaged from acquisitions after 70 minutes through the rest of the session. The steady-state spectra were analyzed with –2Hz/6Hz Lorentzian-to-Gaussian conversion and 16-fold zero-filling followed by Fourier transformation. An LC model approach was used to fit the peak areas of the labeled carbon positions of glutamate C5 and glutamine C5 (Fig. 1C), which overlapped with aspartate C4. Cramer-Rao Lower Bounds were used to estimate the quality of the individual measurements, averaging 5.8% for glutamate and 9.6% for glutamine/aspartate. The aspartate C4 kinetics closely track that of its glutamate precursor [55], thus it is considered to have the same percent enrichment as glutamate C5 and was subtracted from the combined glutamine-aspartate peak. The ^{13}C-Glutamate/^{13}C-Glutamine enrichment ratio was computed using peak areas of glutamate C5 and glutamine C5, (i.e., glutamate-C5/glutamine-C5 * f), where f is the ratio of glutamate/glutamine, measured by reference [56]). Then, EPC was calculated based on the relative ^{13}C enrichment of Glutamate over Glutamine at steady state, as follows: V_{TCAn}/V_{cycle} = [1 - (^{13}C-Glutamate/^{13}C-Glutamine)]/(^{13}C-Glutamate/^{13}C-Glutamine), where ^{13}C-Glutamine and ^{13}C-Glutamate represent the steady state ^{13}C enrichments during the infusion of [1 ^{13}C]-acetate (i.e., ~ 70-120 min after starting infusion) [57].

Statistical Analyses

Before conducting each analysis, the distributions of outcome measure were examined. Data transformation was not needed. Estimates of variation are provided as standard error of mean (*SEM*). Considering that this is a first-in-human study, this study should be considered a first-level pilot study implementing a novel technique, rather than a confirmatory study.

Independent t tests and chi-square tests were used to determine differences between groups. Spearman's rank order was used for correlational analyses. Fisher r-to-z transformation was used to compare correlations between groups. General linear model examined the effects of medication status, including age as covariate. All tests were two-tailed, with the significance threshold set at 0.05. The Statistical Package for the Social Sciences (version 24; IBM) software was used for the analyses.

RESULTS

A total of 34 participants (18 healthy & 16 PTSD+MDD) successfully completed the study procedures. Sex, race, age, height, and weight were not statistically different between the study groups (Table 1). Trauma exposure was not exclusionary, however, only one healthy subject was trauma exposed.

We first investigated the effect of group on EPC. We found a 28% reduction of EPC in the PTSD+MDD (mean±SEM = 2.2±0.2) compared to healthy control (mean±SEM = 3.0±0.2; $t = -3.0$, $df = 32$, $p = 0.005$; Fig. 1). Next, we examined the effect of sex on EPC, which showed no EPC differences between males (mean±SEM = 2.6±0.2) and females (mean±SEM = 2.7±0.2; $t = -0.3$, $df = 32$, $p = 0.75$). However, there was a significant negative correlation between EPC and age ($r = -0.46$, $n = 34$, $p = 0.006$; Fig. 2). Comparing the EPC-age association between study groups showed no statistically significant difference in PTSD+MDD ($r = -0.41$) compared to healthy control ($r = -0.49$; $z = 0.27$, $p = 0.79$). Considering the relationship between age and EPC, we conducted a general linear model analysis examining the effect of diagnosis controlling for age. The general linear model showed significant group effects ($F_{(1,31)} = 7.3$, $p = 0.01$), indicating reduced EPC in PTSD+MDD compared to healthy control, controlling for age.

Finally, we conducted an exploratory analysis to examine whether EPC differed between the subgroups of medicated PTSD+MDD (i.e., on stable SRI antidepressant), unmedicated PTSD+MDD and healthy participants. Controlling for age, a general linear model showed statistically significant subgroup effects ($F_{(2,30)} = 5.3$, $p = 0.01$; Fig. 3). Post-hoc pairwise comparisons found significant reduction in EPC in the unmedicated PTSD+MDD participants, compared to healthy controls ($p = 0.003$). There were no statistically significant differences between medicated PTSD+MDD and each of the unmedicated PTSD+MDD ($p = 0.10$) and healthy control subgroups ($p = 0.17$) (Fig. 3).

DISCUSSION

The study findings provided the first *in vivo* evidence of reduced prefrontal EPC in trauma-exposed individuals with comorbid PTSD and MDD, suggestive of a reduction in glutamatergic synaptic strength in patients. The data also provided supportive evidence about the role of EPC as measured by [1 ^{13}C]-acetate MRS. In particular, the values of EPC in healthy participants

overlapped with only 8 (i.e., 50% of) PTSD+MDD individuals, indicating that EPC is a tightly controlled biomarker in normal conditions. Another promising finding supporting the potential clinical utility of EPC as biomarker is the preliminary evidence that antidepressants appear to affect glutamatergic synaptic strength as measured by EPC. Together, these pilot data underscore the role of the EPC biomarker in the neurobiology and treatment of trauma and stress-related psychopathology.

The use of EPC as measured by ^{13}C-acetate MRS could hold great promise as a powerful translational treatment target biomarker. **1)** The relationship between neuronal energetics (V_{TCAn}) and glutamate cycling (V_{cycle}) is comparable among rodents and humans [47]. This could be highly useful during early stages of drug development, as pharmacoimaging paradigms established in rodents could be readily translated to humans. **2)** EPC is stable across differing level of neuronal activation and brain state, maintaining on average an approximately constant ratio in anesthetized, asleep, and awake brains [10, 47]. This overall stability across brain activity states is a major strength as biomarker, which simplifies acquisition paradigms and could reduce potential state dependent confounding effects across studies. **3)** The EPC ratio was previously related to psychopathology [48]. **4)** Another advantage is that in ^{13}C-acetate MRS, EPC measure is calculated based on the relative ^{13}C enrichment of Glutamate over Glutamine during isotopic steady state as opposed to a lengthy dynamic time course in the magnet. Together, these characteristics will ensure the rigor and reproducibility of the biomarker, as studies targeting EPC would (a) only need to acquire scans during steady state infusion of acetate, without the need for 2h acquisition to capture the full time-course of acetate kinetics. (b) The measure would not necessarily require sophisticated kinetic modeling or various input functions (e.g., plasma enrichment). (c) As a ratio of 2 metabolites acquired concurrently, it also does provide an optimal internal reference that obviates the need for common MRS correction methods (e.g., phantom replacement, tissue composition, etc.). (d) Given its dependence on steady state only, it may also permit the exploration of various routes of acetate administration instead of the intravenous infusion route. (e) Signal to noise is also optimal considering the high level of ^{13}C enrichment during steady state and the fact that it is an average of long acquisition (~ 1h in the current study). Together, these strengths of the EPC measure could significantly reduce the complexity of ^{13}C MRS acquisition and facilitate its deployment at large scale if this biomarker was confirmed to be of clinical utility.

Overall, the findings of the current study highly support the use of EPC as complimentary biomarker to assess the role of glutamatergic synaptic strength in the pathophysiology of trauma and stress-related disorders. As a ratio of V_{TCA}/V_{Cycle}, EPC measured by ^{13}C-acetate MRS does not differentiate between reduction in V_{TCA} or increase in V_{Cycle}, and vice versa. However, this limitation is also a major strength of the biomarker as it is also a ratio of glutamate/glutamine ^{13}C enrichment at steady state, providing ideal internal reference as well as optimal signal to noise. In our previous studies, we used ^{13}C-glucose MRS to measure V_{TCA} and V_{Cycle} independently [8, 48]. Yet, we found the EPC ratio (i.e., V_{TCA}/V_{Cycle}) to be the most salient biomarker. In one ^{13}C-glucose MRS study, we found a 26% reduction in occipital EPC in MDD compared to healthy control (Fig. S3) [48]. In a separate study, we found that the rapid acting antidepressant ketamine significantly increased prefrontal EPC in healthy and MDD participants, as indicated by its differential effects on glutamate and glutamine enrichment [8]. These latter findings were consistent with preclinical data showing differential effects of ketamine on prefrontal glutamate

and glutamine enrichment [58, 59]. Finally, our previous data correlated prefrontal EPC with the psychotomimetic effects of ketamine, suggesting that EPC is not only relevant to antidepressants and stress-related psychopathology but also perhaps to psychosis mechanisms [8].

Another limitation of EPC is the lack of spatial resolution with the current ^{13}C MRS methods, which are limited to large single cortical ROI and do not permit localization to a specific brain region, e.g., anterior cingulate. However, the cortical ROI targeted in this study (Fig. S1) is believed to play a critical role in PTSD+MDD psychopathology. In addition, based on postmortem and preclinical data, the glutamate abnormalities appear to be widespread throughout the prefrontal cortex [14, 60]. Our colleagues are currently developing novel ^{1}H-^{13}C MRS approaches that will provide higher resolution as well as access to deeper brain structures, which could be used in future studies [61].

Conclusion

The findings of this pilot study support the glutamate synaptic dysconnectivity models of trauma and stress-related psychopathology [1, 6]. In particular, it shows 28% reduction in prefrontal EPC in PTSD+MDD, with a limited overlap between patients and healthy individuals (Fig. 1). These findings are comparable to previous findings in occipital EPC measured by ^{13}C-glucose MRS [48], suggesting widespread cortical disruption in EPC with tightly controlled EPC values in normal condition. Another finding is the negative correlation between age and EPC, raising the possibility that the observed reduction in cortical EPC might be consistent with a phenomenon of accelerated aging in trauma and stress-related disorders [62]. Finally, the study provided preliminary evidence showing an effect of medication status on prefrontal EPC. The data suggested a partial normalization of EPC values following stable treatment with an SRI antidepressant. Future studies should further investigate the effect of antidepressants on EPC and examine whether the prefrontal EPC disruption is related to trauma exposure, to the PTSD+MDD severity, or to both.

FUNDING AND DISCLOSURE

Funding and research support were provided by NIMH (R01MH112668), NIAAA (R01AA021984), the VA National Center for PTSD, Brain & Behavior Foundation (NARSAD), Clinical Neuroscience Research Unit (CNRU) at Connecticut Mental Health Center, and Yale Center for Clinical Investigation (YCCI UL1 RR024139), an NIH Clinical and Translational Science Award (CTSA). LAA receives salary support from the VA Clinical Sciences Research & Development (IK2-CX0001873) and the American Foundation for Suicide Prevention (YIG-0-004-16). The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors, the Department of Veterans Affairs, NIH, or the U.S. Government.

Dr. Abdallah has served as a consultant, speaker and/or on advisory boards for Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint, and FSV7, and as editor of *Chronic Stress* for Sage Publications, Inc. He also filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (Aug 20, 2018). Dr. Krystal is a consultant for Aptinyx, Inc., Atai Life Sciences, AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation,

Bionomics, Limited (Australia), Boehringer Ingelheim International, Cadent Therapeutics, Inc., Clexio Bioscience, Ltd., COMPASS Pathways, Limited, United Kingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Greenwich Biosciences, Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd. Dr. Krystal also reports the following disclosures: **Scientific Advisory Board:** Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cadent Therapeutics, Inc. (Clinical Advisory Board), Cerevel Therapeutics, LLC, EpiVario, Inc., Eisai, Inc., Lohocla Research Corporation, Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., RBNC Therapeutics, Inc., Tempero Bio, Inc., Terran Biosciences, Inc. **Stock:** Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc. **Stock Options:** Biohaven Pharmaceuticals Medical Sciences, EpiVario, Inc., RBNC Therapeutics, Inc., Terran Biosciences, Inc. Tempero Bio, Inc. **Income Greater than $10,000: Editorial Board:** Editor - Biological Psychiatry. **Patents and Inventions:** (1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995. **(2)** Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017. **(3)** Charney D, Krystal JH, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3/14/2017.   Licensed to Janssen Research & Development. **(4)** Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University "Methods for Treating Suicidal Ideation", Patent Application No. 15/379,013 filed on December 14, 2016 by Yale University Office of Cooperative Research. **(5)** Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research. **(6)** Chekroud, A., Gueorguieva, R., & Krystal, JH. "Treatment Selection for Major Depressive Disorder" [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University. **(7)** Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01. **(8)** Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01. **On Non-Federal Research Support:** AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant "Center for Translational Neuroscience of Alcoholism [CTNA-4] Novartis provides the drug, Mavoglurant, for research related to NIAAA grant "Center for Translational Neuroscience of Alcoholism [CTNA-4] Dr. Gueorguieva discloses royalties from book "Statistical Methods in Psychiatry and Related Fields" published by CRC Press, honorarium as a member of the Working Group for PTSD Adaptive Platform Trial of Cohen Veterans Bioscience and a United States patent application 20200143922 by Yale University: Chekroud, A., Krystal, J., Gueorguieva, R. and Chandra, A. "Methods and Apparatus for Predicting Depression Treatment Outcomes". Dr. Sanacora has received consulting fees from Alkermes, Allergan, AstraZeneca, Avanier Pharmaceuticals, Axsome Therapeutics, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Clexio Biosciences, Denovo Biopharma, EMA

Wellness, Engrail, Gilgamesh, Hoffmann–La Roche, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Minerva Neurosciences, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW labs. **Scientific Advisory Board:** Biohaven Pharmaceuticals, Gilgamesh Pharmaceuticals. VistaGen Therapetutics **Stock:** Biohaven Pharmaceuticals, Gilead Sciences. **Stock Options:** Biohaven Pharmaceuticals Medical Sciences, **Income Greater than $10,000:** Biohaven pharmaceteuticals**. Patents and Inventions:** (**1**) Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017. (**2**) Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01. **On Non-Federal Research Support:** Dr. Sanacora has received research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffmann–La Roche, Merck, Naurex, Servier Pharmaceuticals, and Usona. No-cost medication was provided to Dr. Sanacora for an NIH-sponsored study by Sanofi-Aventis. All other authors declared no conflict of interests.

ACKNOWLEDGMENTS

The authors would like to thank the individuals who participated in these studies for their invaluable contribution.

AUTHORS CONTRIBUTION

Conceptualization, C.G.A., G.S., J.H.K., D.L.R. and G.F.M.; Methodology, C.G.A., H.M.DF., R.A.dG., D.L.R. and G.F.M.; Data Curation: C.G.A., L.A.A., L.J., P.P., A.C., C.L.A., J.R., B.K., and G.F.M.; Formal Analysis, C.G.A. and R.G.; Investigation, C.G.A., L.A.A., L.J., P.P., A.C., C.L.A., J.R., B.K., R.G., G.S., J.H.K., D.L.R. and G.F.M.; Writing – Original Draft, C.G.A.; Writing – Review/Edit, all authors; Funding Acquisition, C.G.A., J.H.K. and G.F.M.; Resources, C.G.A., L.A.A. and G.F.M.; Supervision, C.G.A. and G.F.M.

Figure Legends

Figure 1. The effects of diagnosis on glutamate neurotransmission strength as measured by energy per cycle (EPC). Participants diagnosed with comorbid posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) were found to have 28% reduction in EPC compared to healthy controls. EPC is a measure of neuronal energetic needs (V_{TCAn}) per glutamate/glutamine cycling (V_{Cycle}), which is computed from the relative carbon-13 enrichment of glutamine and glutamate during steady state of [1-^{13}C]-acetate intravenous infusion. The dotted line, at 2.146, marks the lowest EPC value among healthy participants. It shows that the EPC values of only 8 (50%) PTSD+MDD individuals overlapped with those of healthy control.

Figure 2. The association between age and glutamate neurotransmission strength as measured by energy per cycle (EPC). There is a significant negative correlation between age and EPC in the full cohort, as well as in the healthy and patient groups considered separately. EPC is a measure of neuronal energetic needs (V_{TCAn}) per glutamate/glutamine cycling (V_{Cycle}), which is computed from the relative carbon-13 enrichment of glutamine and glutamate during steady state of [1-^{13}C]-acetate intravenous infusion. Abbreviations: PTSD = posttraumatic stress disorder; MDD = major depressive disorder.

Figure 3. The effect of antidepressant treatment on glutamate neurotransmission strength as measured by energy per cycle (EPC). There was a significant effect of medication status on EPC, with unmedicated PTSD+MDD individuals showing the lowest average EPC. Antidepressant treatment with serotonin reuptake inhibitors appears to partially normalize EPC values compared to healthy control. EPC is a measure of neuronal energetic needs (V_{TCAn}) per glutamate/glutamine cycling (V_{Cycle}), which is computed from the relative carbon-13 enrichment of glutamine and glutamate during steady state of [1-^{13}C]-acetate intravenous infusion.

Table 1. Demographics and Clinical Characteristics

	PTSD+**MDD** (n=16)	**Healthy** (n=18)	*p* value*
Female	10 (62%)	11 (61%)	0.93
White	9 (56%)	11 (61%)	0.77
Age (years)	39.5±3.3	34.3±2.9	0.25
Height (inches)	65.7±1.0	65.3±0.8	0.60
Weight (lbs.)	169±12	148±8	0.16
PCL	45.4±3.9	1.8±0.7	< 0.01
QIDS	14.5±0.9	1.7±0.4	< 0.01
Unmedicated	7 (44%)		

* Chi-square and independent t tests were used to compare groups. *Abbreviations*: PTSD = posttraumatic stress disorder; MDD = major depressive disorder; PCL = PTSD checklist; QIDS = Quick Inventory of Depressive Symptomatology.

References

1.   Abdallah CG, Averill LA, Akiki TJ, Raza M, Averill CL, Gomaa H, et al. The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. Annu Rev Pharmacol Toxicol. 2019;59:171-89. doi:10.1146/annurev-pharmtox-010818-021701

2.   Pitman RK, Rasmusson AM, Koenen KC, Shin LM, Orr SP, Gilbertson MW, et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci. 2012;13(11):769-87. doi:10.1038/nrn3339

3.   Abdallah CG, Southwick SM, Krystal JH. Neurobiology of posttraumatic stress disorder (PTSD): A path from novel pathophysiology to innovative therapeutics. Neurosci Lett. 2017;649:130-2. doi:10.1016/j.neulet.2017.04.046

4.   Akiki TJ, Averill CL, Abdallah CG. A Network-Based Neurobiological Model of PTSD: Evidence From Structural and Functional Neuroimaging Studies. Curr Psychiatry Rep. 2017;19(11):81. doi:10.1007/s11920-017-0840-4

5.   Sheynin J, Liberzon I. Circuit dysregulation and circuit-based treatments in posttraumatic stress disorder. Neurosci Lett. 2017;649:133-8. doi:10.1016/j.neulet.2016.11.014

6.   Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neurosci Lett. 2017;649:147-55. doi:10.1016/j.neulet.2016.11.064

7.   Davis MT, Holmes SE, Pietrzak RH, Esterlis I. Neurobiology of Chronic Stress-Related Psychiatric Disorders: Evidence from Molecular Imaging Studies. Chronic Stress. 2017;1:2470547017710916.

8.   Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018. doi:10.1038/s41386-018-0136-3

9.   Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44(1):5-21. doi:10.1016/j.neuron.2004.09.012

10.   Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci. 2004;27(8):489-95. doi:10.1016/j.tins.2004.06.005

11.   Yu Y, Herman P, Rothman DL, Agarwal D, Hyder F. Evaluating the gray and white matter energy budgets of human brain function. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2018;38(8):1339-53. doi:10.1177/0271678X17708691

12.   Howarth C, Gleeson P, Attwell D. Updated energy budgets for neural computation in the neocortex and cerebellum. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2012;32(7):1222-32. doi:10.1038/jcbfm.2012.35

13.   Herman P, Sanganahalli BG, Blumenfeld H, Rothman DL, Hyder F. Quantitative basis for neuroimaging of cortical laminae with calibrated functional MRI. Proc Natl Acad Sci U S A. 2013;110(37):15115-20. doi:10.1073/pnas.1307154110

14.   Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2012;13(1):22-37. doi:10.1038/nrn3138

15.   Kadriu B, Greenwald M, Henter ID, Gilbert JR, Kraus C, Park LT, et al. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. Int J Neuropsychopharmacol. 2021;24(1):8-21. doi:10.1093/ijnp/pyaa087

16.   Kraus C, Wasserman D, Henter ID, Acevedo-Diaz E, Kadriu B, Zarate CA, Jr. The influence of ketamine on drug discovery in depression. Drug Discov Today. 2019. doi:10.1016/j.drudis.2019.07.007

17.   Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, et al. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Curr Psychiatry Rep. 2017;19(10):74. doi:10.1007/s11920-017-0829-z

18.   Averill LA, Abdallah CG, Pietrzak RH, Averill CL, Southwick SM, Krystal JH, et al. Combat Exposure Severity is Associated with Reduced Cortical Thickness in Combat Veterans: A Preliminary Report. Chronic Stress. 2017;1:2470547017724714. doi:10.1177/2470547017724714

19.   Schmaal L, Hibar DP, Samann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry. 2017;22(6):900-9. doi:10.1038/mp.2016.60

20.   Wang X, Xie H, Chen T, Cotton AS, Salminen LE, Logue MW, et al. Cortical volume abnormalities in posttraumatic stress disorder: an ENIGMA-psychiatric genomics consortium PTSD workgroup mega-analysis. Mol Psychiatry. 2020. doi:10.1038/s41380-020-00967-1

21.   Wrocklage KM, Averill LA, Cobb Scott J, Averill CL, Schweinsburg B, Trejo M, et al. Cortical thickness reduction in combat exposed U.S. veterans with and without PTSD. Eur Neuropsychopharmacol. 2017;27(5):515-25. doi:10.1016/j.euroneuro.2017.02.010

22.   Akiki TJ, Averill CL, Wrocklage KM, Schweinsburg B, Scott JC, Martini B, et al. The Association of PTSD Symptom Severity with Localized Hippocampus and Amygdala Abnormalities. Chronic Stress. 2017;1:2470547017724069. doi:10.1177/2470547017724069

23.   Gosnell S, Meyer M, Jennings C, Ramirez D, Schmidt J, Oldham J, et al. Hippocampal volume in psychiatric diagnoses: Should psychiatry biomarker research account for comorbidities? Chronic Stress. 2020;4:2470547020906799. doi:10.1177/2470547020906799

24.   Logue MW, van Rooij SJH, Dennis EL, Davis SL, Hayes JP, Stevens JS, et al. Smaller Hippocampal Volume in Posttraumatic Stress Disorder: A Multisite ENIGMA-PGC Study: Subcortical Volumetry Results From Posttraumatic Stress Disorder Consortia. Biol Psychiatry. 2018;83(3):244-53. doi:10.1016/j.biopsych.2017.09.006

25.   Negreira AM, Abdallah CG. A Review of fMRI Affective Processing Paradigms Used in the Neurobiological Study of Posttraumatic Stress Disorder. Chronic Stress. 2019;3:2470547019829035. doi:10.1177/2470547019829035

26.   Seidemann R, Duek O, Jia R, Levy I, Harpaz-Rotem I. The Reward System and Post-Traumatic Stress Disorder: Does Trauma Affect the Way We Interact With Positive Stimuli? Chronic Stress (Thousand Oaks). 2021;5:2470547021996006. doi:10.1177/2470547021996006

27.   Abdallah CG, Averill CL, Ramage AE, Averill LA, Alkin E, Nemati S, et al. Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment. Chronic Stress. 2019;3:2470547019838971. doi:10.1177/2470547019838971

28.   Abdallah CG, Averill CL, Ramage AE, Averill LA, Goktas S, Nemati S, et al. Salience Network Disruption in U.S. Army Soldiers With Posttraumatic Stress Disorder. Chronic Stress. 2019;3:2470547019850467. doi:10.1177/2470547019850467

29.   Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, et al. Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2(7):566-74. doi:10.1016/j.bpsc.2017.04.006

30.   Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology. 2017;42(6):1210-9. doi:10.1038/npp.2016.186

31.   Abdallah CG, Dutta A, Averill CL, McKie S, Akiki TJ, Averill LA, et al. Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients. Chronic Stress. 2018;2:2470547018796102.

32.   Abdallah CG, Wrocklage KM, Averill CL, Akiki T, Schweinsburg B, Roy A, et al. Anterior hippocampal dysconnectivity in posttraumatic stress disorder: a dimensional and multimodal approach. Translational psychiatry. 2017;7(2):e1045. doi:10.1038/tp.2017.12

33.   Holmes SE, Scheinost D, DellaGioia N, Davis MT, Matuskey D, Pietrzak RH, et al. Cerebellar and prefrontal cortical alterations in PTSD: structural and functional evidence. Chronic Stress. 2018;2. doi:10.1177/2470547018786390

34.   Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10(1):1529. doi:10.1038/s41467-019-09562-7

35.   Murrough JW, Abdallah CG, Anticevic A, Collins KA, Geha P, Averill LA, et al. Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Hum Brain Mapp. 2016;37(9):3214-23. doi:10.1002/hbm.23235

36.   Nemati S, Abdallah CG. Increased Cortical Thickness in Patients With Major Depressive Disorder Following Antidepressant Treatment. Chronic Stress (Thousand Oaks). 2020;4:2470547019899962. doi:10.1177/2470547019899962

37.   Scheinost D, Holmes SE, DellaGioia N, Schleifer C, Matuskey D, Abdallah CG, et al. Multimodal Investigation of Network Level Effects Using Intrinsic Functional Connectivity, Anatomical Covariance, and Structure-to-Function Correlations in Unmedicated Major Depressive Disorder. Neuropsychopharmacology. 2018;43(5):1119-27. doi:10.1038/npp.2017.229

38.   Wang L, Dai Z, Peng H, Tan L, Ding Y, He Z, et al. Overlapping and segregated resting-state functional connectivity in patients with major depressive disorder with and without childhood neglect. Hum Brain Mapp. 2014;35(4):1154-66. doi:10.1002/hbm.22241

39.   Abdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N, Sanacora G, et al. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2(5):449-56. doi:10.1016/j.bpsc.2017.03.019

40.   Holmes SE, Girgenti MJ, Davis MT, Pietrzak RH, DellaGioia N, Nabulsi N, et al. Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proc Natl Acad Sci U S A. 2017;114(31):8390-5. doi:10.1073/pnas.1701749114

41.   Meyerhoff DJ, Mon A, Metzler T, Neylan TC. Cortical gamma-aminobutyric acid and glutamate in posttraumatic stress disorder and their relationships to self-reported sleep quality. Sleep. 2014;37(5):893-900. doi:10.5665/sleep.3654

42.   Pennington DL, Abe C, Batki SL, Meyerhoff DJ. A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res. 2014;224(3):281-7. doi:10.1016/j.pscychresns.2014.09.004

43.   Rosso IM, Crowley DJ, Silveri MM, Rauch SL, Jensen JE. Hippocampus Glutamate and N-Acetyl Aspartate Markers of Excitotoxic Neuronal Compromise in Posttraumatic Stress Disorder. Neuropsychopharmacology. 2017;42(8):1698-705. doi:10.1038/npp.2017.32

44.   Yang ZY, Quan H, Peng ZL, Zhong Y, Tan ZJ, Gong QY. Proton magnetic resonance spectroscopy revealed differences in the glutamate + glutamine/creatine ratio of the anterior cingulate cortex between healthy and pediatric post-traumatic stress disorder patients diagnosed after 2008 Wenchuan earthquake. Psychiatry Clin Neurosci. 2015. doi:10.1111/pcn.12332

45.   Paulus MP, Thompson WK. The Challenges and Opportunities of Small Effects: The New Normal in Academic Psychiatry. JAMA psychiatry. 2019;76(4):353-4. doi:10.1001/jamapsychiatry.2018.4540

46.   Rothman DL, De Feyter HM, de Graaf RA, Mason GF, Behar KL. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011;24(8):943-57. doi:10.1002/nbm.1772

47.   Hyder F, Rothman DL, Bennett MR. Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels. Proc Natl Acad Sci U S A. 2013;110(9):3549-54. doi:10.1073/pnas.1214912110

48.   Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL, et al. Glutamate metabolism in major depressive disorder. Am J Psychiatry. 2014;171(12):1320-7. doi:10.1176/appi.ajp.2014.14010067

49.   Li S, Zhang Y, Wang S, Araneta MF, Johnson CS, Xiang Y, et al. 13C MRS of occipital and frontal lobes at 3 T using a volume coil for stochastic proton decoupling. NMR in biomedicine. 2010;23(8):977-85. doi:10.1002/nbm.1524

50.   Li S, Zhang Y, Wang S, Yang J, Ferraris Araneta M, Farris A, et al. In vivo 13C magnetic resonance spectroscopy of human brain on a clinical 3 T scanner using [2-13C]glucose infusion and low-power stochastic decoupling. Magn Reson Med. 2009;62(3):565-73. doi:10.1002/mrm.22044

51.   Sailasuta N, Robertson LW, Harris KC, Gropman AL, Allen PS, Ross BD. Clinical NOE 13C MRS for neuropsychiatric disorders of the frontal lobe. Journal of magnetic resonance. 2008;195(2):219-25. doi:10.1016/j.jmr.2008.09.012

52.   Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, et al. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2010;30(1):211-21. doi:10.1038/jcbfm.2009.197

53.   Moshier SJ, Lee DJ, Bovin MJ, Gauthier G, Zax A, Rosen RC, et al. An Empirical Crosswalk for the PTSD Checklist: Translating DSM-IV to DSM-5 Using a Veteran Sample. J Trauma Stress. 2019;32(5):799-805. doi:10.1002/jts.22438

54.   Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-

report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-83. doi:S0006322302018668 [pii]

55.   Gruetter R, Seaquist ER, Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am J Physiol Endocrinol Metab. 2001;281(1):E100-12.

56.   Lally N, An L, Banerjee D, Niciu MJ, Luckenbaugh DA, Richards EM, et al. Reliability of 7T (1) H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation. J Magn Reson Imaging. 2016;43(1):88-98. doi:10.1002/jmri.24970

57.   Lebon V, Petersen KF, Cline GW, Shen J, Mason GF, Dufour S, et al. Astroglial contribution to brain energy metabolism in humans revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci. 2002;22(5):1523-31.

58.   Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry. 2012;71(11):1022-5. doi:10.1016/j.biopsych.2011.11.006

59.   Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry. 2017;22(1):120-6. doi:10.1038/mp.2016.34

60.   Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77. doi:10.1016/j.neuropharm.2011.07.036

61.   Rothman DL, de Graaf RA, Hyder F, Mason GF, Behar KL, De Feyter HM. In vivo (13) C and (1) H-[(13) C] MRS studies of neuroenergetics and neurotransmitter cycling, applications to neurological and psychiatric disease and brain cancer. NMR Biomed. 2019;32(10):e4172. doi:10.1002/nbm.4172

62.   Bersani FS, Mellon SH, Reus VI, Wolkowitz OM. Accelerated aging in serious mental disorders. Curr Opin Psychiatry. 2019;32(5):381-7. doi:10.1097/YCO.0000000000000525